Table 4.
Incremental Cost-Effectiveness of Cost per Quality-Adjusted Life-Year by Strategies from the Base Case Analysis and Three One-Way Sensitivity Analyses over a 20-Year Time Horizon of Model
| Scenario | Strategy | Cost (U.S. dollars) | Incremental cost (U.S. dollars) | Effectiveness (QALYs) | Incremental effectiveness (QALYs) | ICER (cost per QALY) |
|---|---|---|---|---|---|---|
| Base case analysis | UC | $116,242 | — | 8.351 | — | — |
| DOC | $121,553 | $5,311 | 8.467 | 0.117 | $45,495 | |
| Societal perspectivea | UC | $137,084 | — | 8.351 | — | — |
| DOC | $141,993 | $4,909 | 8.467 | 0.117 | $42,051 | |
| Mirror the DOC cohortb | UC | $152,647 | — | 7.236 | — | — |
| DOC | $157,859 | $5,212 | 7.321 | 0.085 | $61,243 | |
| Mirror the UC cohortc | UC | $153,333 | — | 7.214 | — | — |
| DOC | $158,552 | $5,219 | 7.299 | 0.084 | $61,813 |
a
The ICER of cost per QALY was calculated from the societal perspective.
b
Initial proportions of patients in 5 health states at the start of the model were changed to mirror the DOC cohort, and then the ICER of cost per QALY was calculated from the societal perspective.
c
Initial proportions of patients in 5 health states at the start of the model were changed to mirror the UC cohort, and then the ICER of cost per QALY was calculated from the societal perspective.